AbbVie Inc. · 2024 Q3
ReportedOct 30, 2024
Period endedSep 30, 2024
Rule of 40+40
Reported this quarter
Revenue
$14.46B
QoQ +0.0%
YoY +3.8%
EPS
$0.88
QoQ +14.3%
YoY -12.0%
Free Cash Flow
$5.20B
QoQ +156.1%
YoY -29.3%
Gross Margin
70.9%
QoQ -0.1 pp
YoY +2.2 pp
FCF Margin
35.9%
QoQ +21.9 pp
YoY -16.9 pp
P/E Ratio
65.2
QoQ +21.0%
YoY +74.4%
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1551152.
HTML
8-K results announcement
Filed Oct 30, 2024
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
462 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-Q quarterly report
Period ended Sep 30, 2024, filed Nov 4, 2024
ZIP
XBRL data bundle
Structured financial statements from the 10-Q
JSON
Company facts (XBRL)
Every figure ABBV has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for 2024 Q3, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings